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In 2010, the NC3Rs published the Animal Research: 
Reporting of In Vivo Experiments (ARRIVE) guidelines 
to improve the reporting of animal research. Despite 
considerable levels of support from the scientific community, 
the impact on the quality of reporting in animal research 
publications has been limited. This position paper highlights 
the strategy of an expert working group established to 
revise the guidelines and facilitate their uptake. The group’s 
initial work will focus on three main areas: prioritisation 
of the ARRIVE items into a tiered system, development of 
an explanation and elaboration document, and revision of 
specific items.
Scientists, funders and the public are increas-
ingly concerned about the reproducibility of 
preclinical research, including studies that 
use animals.1 While the reasons for failing to 
reproduce the methods and findings of a study 
are complex and wide ranging, a lack of trans-
parency stemming from poor reporting clearly 
contributes to the problem.2 The NC3Rs 
coordinated the development of the Animal 
Research: Reporting of In Vivo Experiments 
(ARRIVE) reporting guidelines in 2010.3 
The guidelines consist of a 20-item checklist 
that covers the key information that should 
be described in a scientific publication. The 
goal is to ensure that the reader can assess the 
methodological rigour of the experiment, and 
other scientists can evaluate and reproduce the 
methods.
To date, over a thousand journals, funders 
and research institutes support and endorse 
ARRIVE.4 The guidelines have contributed to 
the understanding of the issues that compro-
mise reproducibility, and prompted actions to 
improve the situation. For example, major UK 
funders now explicitly mandate a comprehen-
sive description of the study design, including 
plans to minimise experimental bias. Grant 
applicants must also explain how the number 
of animals to be used was decided and provide 
detailed statistical analysis plans to ensure that 
peer reviewers and panel members can fully 
assess the rigour and validity of the proposed 
research.5
Have the guidelines improved reporting? 
In the 7 years since the ARRIVE guidelines 
were published, researchers have sought to 
measure the impact of the guidelines on the 
quality of reporting,6 7 with mixed results. A 
recent randomised controlled trial in PLOS 
ONE8 showed that mandating the comple-
tion of an ARRIVE checklist with manuscript 
submission, with no additional emphasis on 
reporting during the editorial process, did 
not improve adherence to the guidelines in 
published papers. While these results are disap-
pointing to those seeking immediate change, 
this study provides an evidence base to improve 
the guidelines, and ultimately the rigour and 
reproducibility of animal studies.
In the light of methodological advances in 
science and experience with the guidelines 
since their introduction, the NC3Rs convened 
an international working group to revise 
them. The authors here are members of the 
working group, and include funders, journal 
editors, statisticians, methodologists and animal 
researchers from academia and industry. The 
aim of this report is to provide readers and 
stakeholders with information about areas that 
we are currently working on to improve the 
ARRIVE guidelines during 2018. This work 
includes:
Prioritising the items of the ArriVe 
guidelines
Each of the 20 items of the ARRIVE guide-
lines are important for various reasons. For 
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6), how the animals were allocated to groups (item 11) and 
how the sample size was chosen (item 10) are crucial to 
understand how reliable and robust the findings are. Simi-
larly, items such as the experimental procedures (item 7) 
or animal characteristics (item 8) are important to ensure 
that papers contain enough information for others to repli-
cate and build upon the study. Other ARRIVE items such as 
the scientific background (item 3) and relevance to other 
species (item 19) provide information about the context 
of the study.3 In their current form, the guidelines do not 
lend themselves easily to retrospective evaluation; assessing 
whether a manuscript includes all 20 ARRIVE items neces-
sitates operationalising the checklist into over a hundred 
separate elements.9 To enable a more manageable approach 
for assessing the quality of reporting in manuscripts, we 
plan to organise the items in the ARRIVE guidelines into 
tiers reflecting different levels of priority; tier 1 items will 
include the most important items on which initial efforts 
from authors, reviewers and journals should focus. We will 
carry out a Delphi exercise,10 to structure communications 
within the working group and with external stakeholders, 
and reach a consensus on the criteria defining the tiers, and 
on the most appropriate tier for each item. Importantly, the 
tiers will also enable a stepwise approach for journals and 
others to improve reporting standards, the objective being 
that ultimately all manuscripts will include all elements of 
the guidelines.
Prioritising subsets of items in this way will provide 
straightforward measures for journals, institutions and 
researchers. We anticipate that journals will continue to 
recommend that authors follow the ARRIVE guidelines 
in their entirety, to encourage comprehensive reporting. 
At the same time, focusing editorial efforts on a smaller 
number of key pieces of information that can be particu-
larly scrutinised by editors and reviewers will enable a more 
rapid assessment of both individual manuscript quality, and 
the overall impact of their improvement strategies. This is 
an approach already used by some journals.11 12 With the 
use of text mining and machine learning technologies, 
automating many of these checks is possible,13 and coor-
dinating work on top tier items will accelerate the develop-
ment of tools to facilitate this.
deVeloPing An exPlAnAtion And elAborAtion doCument
Understanding the rationale for a set of guidelines is essen-
tial for securing support from the scientific community. The 
Consolidated Standards of Reporting Trials (CONSORT) 
statement, for example, has been accompanied by an Expla-
nation and Elaboration document since its second iteration 
in 2001.14 This summarises the evidence behind each item 
of the guidelines and explains why each item is important 
to include in a manuscript.
A recent survey of in vivo researchers carried out by the 
NC3Rs15 highlighted that the main reason for authors not 
including an ARRIVE item in a manuscript was because 
they did not think it was necessary to disclose that infor-
mation. Incomplete reporting is also exacerbated by the 
fact that some of the concepts included in the guidelines, 
such as measures to reduce bias, are not well understood 
by researchers or not considered relevant for their own 
research.16 To address this, we are now developing an 
Explanation and Elaboration document for the ARRIVE 
guidelines. This document will provide explanations and 
definitions for technical terms, empirical evidence in 
support of each ARRIVE item, as well as examples from the 
published literature on how authors might report items. 
Following publication of the document, the information 
will be made readily accessible via a dedicated ARRIVE 
website.
reVising the guidelines
We are reviewing specific ARRIVE items to ensure that the 
guidance provided is in line with the current best evidence. 
Where evidence is lacking we will seek to develop it. The 
revision is an opportunity to improve the clarity of individual 
items, ensure their relevance across the breadth of in vivo 
research and enhance the logical flow of information within 
the guidelines. In recent years, scientific organisations 
such as publishers and funders have produced additional 
guidance to improve the reporting of preclinical research 
(eg, NINDS’s call for greater transparency in preclinical 
research,17 NIH’s Principles and Guidelines for Reporting 
Preclinical Research,18 Nature’s Reporting Life Sciences 
Research checklist,19 Cell guidelines,20 British Journal of Phar-
macology’s guidance for reporting experimental design and 
analysis21). Such guidelines will be taken into consideration 
in the revision. The ARRIVE guidelines are not intended 
to supersede journal or model-specific guidelines but the 
level of support from funders and journals puts ARRIVE 
in a unique position to serve as the basis for more special-
ised guidelines. The publishing landscape has also evolved 
over the last decade and the revised guidelines will reflect 
these changes by providing advice on emerging best prac-
tice. Additionally, external stakeholders with expertise in 
preclinical research reporting will be able to suggest further 
revisions via the above-mentioned Delphi exercise.
The scope of the ARRIVE guidelines is broad; they are 
designed to be flexible and accommodate the reporting of 
comparative studies in a wide range of research areas. As 
such, the existing guidelines were formulated to provide 
general advice for heterogeneous study types. However, 
recent calls have been made to encourage researchers to 
explicitly distinguish between exploratory and hypothe-
sis-testing studies.22 23 For hypothesis-testing studies that are 
using inferential statistics, the manuscript would be expected 
to describe the primary and secondary outcome measures, 
the parameters used in the sample size calculation, whether 
the study protocol was preregistered, and if so, where it 
can be found. Exploratory studies, on the other hand, are 
designed to generate hypotheses; they might confer the 
same importance to all outcomes measured, might justify 
the sample size based on feasibility or experience and 
would report only descriptive statistics. Thus, the reporting 
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can differ, and the revision will ensure that the updated 
guidelines provide adequate advice for both.
finAl remArks
Revising the guidelines is just the first step; their primary 
goal is to improve transparency and the standards of 
reporting, but transparent reporting can be used to address 
common weaknesses in the design and conduct of animal 
research and encourage researchers to adopt more rigorous 
scientific practices. Ultimately, the ARRIVE guidelines will 
form the basis for a powerful suite of tools and resources 
that provide optimal support for researchers to improve 
the design, conduct and reporting of in vivo research; this 
will also benefit research users and stakeholders tasked with 
assessing the quality and translational value of preclinical 
research.
Improving reporting should be a community-wide effort, 
and the working group recognises the importance of 
engaging others in the evolution of the ARRIVE guidelines. 
It is essential that this endeavour includes scientists from a 
range of research fields and countries, and we encourage 
the community to share their experience and views.
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